Amyloid and neurodegeneration: Converging and diverging paths

Neurology

Volumn 81, Issue 20, 2013, Pages 1728-1729

  Klunk, William E ^a   Perani, Daniela ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

AMYLOIDOSIS; BRAIN ATROPHY; DEFAULT MODE NETWORK; EDITORIAL; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AMYLOID; ANILINE COMPOUNDS; COGNITION DISORDERS; HUMANS; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84888270494     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000435568.38352.2e     Document Type: Editorial

References (14)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound B. Ann Neurol 2004;55:306-319.
2. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
4. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7: 270-279.
5. Sperling R, DonohueM, Aisen P. The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer's disease. Alzheimers Dement 2012;8:P425-P426.
6. Jack CR Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81:1732-1740.
7. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
8. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31: 1275-1283.
9. Garibotto V, Borroni B, Kalbe E, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 2008;71:1342-1349.
10. Garibotto V, Tettamanti M, Marcone A, et al. Cholinergic activity correlates with reserve proxies in Alzheimer's disease. Neurobiol Aging 2013;34:e2613-e2698.
11. Caroli A, Prestia A, Chen K, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 2012;53:592-600.
12. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765-775.
13. Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology 2012;78:342-351.
14. Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011;32:S20-S36.